To sum up, we suggest that developing inhibitors that affect the JAK/STAT signaling pathway in cancer cells through various pathways, such as phosphorylation in serine and tyrosine residues, acetylation, methylation, and glycosylation may be a potential therapeutic strategy for a variety of hematological malignancies. This evidence concerns the gene SOAT1 and hematologic disorder.